Ehlers-Danlos syndrome encompasses a group of inherited disorders of connective tissue, some of which are characterised by abnormalities of coliagen metabolism. The chromosomal location, identified genes and biochemical defects, inheritance pattern, and clinical features for the various known subtypes are outlined. Prenatal diagnosis is possible for types IV, VI, VIIAI, and VIIA2. An unusual presentation of type IV EhlersDanlos syndrome in a 16 year old boy with an anterior myocardial infarction resulting from dissection of the left anterior descending coronary artery is reported here. A clinical diagnosis of type IV Ehlers-Danlos syndrome was made subsequently and confirmed by the reduced production, impaired secretion, and abnormally slow electrophoretic migration of type III collagen, indicating an underlying mutation in the COL3A1 gene. This patient represents the first case of type IV Ehlers-Danlos syndrome with symptomatic coronary artery dissection.
Ehlers-Danlos syndrome refers to a heterogeneous group of connective tissue disorders, manifested by a wide range of clinical presentations including skin fragility, skin hyperextensibility, and joint hypermobility. Fourteen distinct types have been described on the basis of clinical and genetic differences' and the molecular basis of several of them has been identified. It is important to specify the type of Ehlers-Danlos syndrome because the natural history, clinical management, and mode of inheritance differ depending on the type. In addition to generalised involvement of the vasculature, the heart, its valves and the great vessels may also be involved in several of the Ehlers-Danlos syndrome types. Many patients with Ehlers-Danlos syndrome-like clinical findings do not fit the general classification, and as more biochemical studies are completed, the classification is likely to expand. Important considerations from the clinical perspective include the mode of inheritance and whether the natural history can be predicted from family or biochemical studies. It is vital to distinguish the recessively inherited type VI because prenatal diagnosis is potentially available. It is also important to identify patients with type IV so that clear discussion of risks (related to sports, pregnancy, and surgery in particular) can occur in a non-emergency setting.
The evaluation of patients suspected of having Ehlers-Danlos syndrome should include careful physical examination and a detailed family history. Biochemical studies of collagens synthesised by fibroblasts cultured from full thickness dermal punch biopsy specimens can identify patients with type IV, VI, and some patients with type VII EhlersDanlos syndrome.
Type IV Ehlers-Danlos syndrome is dominantly inherited, with 50 per cent of cases representing new mutations.' It is characterised clinically by thin non-hyperelastic skin, bruising, poor wound healing, mild joint hypermobility, and spontaneous rupture of arteries, the colon, and gravid uterus, and biochemically by deficiency of type III collagen. Type III collagen deficiency results from mutations in one of the genes for the type III collagen proal (III) chain (COL3A1). COL3A1 mutations reported to date include genomic deletions, exon skipping, and point mutations,' which compromise the collagen triple helix and result in impaired secretion, excessive post-translational modification, and reduced stability ofthe type mI collagen molecules.
We report an adolescent male in whom the diagnosis of type IV Ehlers-Danlos syndrome was made after he suffered a myocardial infarction secondary to coronary artery dissection. This is the only reported case of symptomatic coronary artery dissection in type IV Ehlers-Danlos syndrome. another episode of acute chest pain 1 year after original presentation; thoracic computed tomogram was normal. He was managed conservatively and given atenolol.
The patient's older brother also had severe bilateral talipes equinovarus at birth. Pyloric stenosis was corrected surgically at 1 month of age. He had a history of easy bruising and bleeding, a tendency to keloid scar formation, and suffered recurrent dislocations of his right shoulder. He had numerous surgical procedures to his feet. At 12 years of age he suffered abdominal trauma during sport; haemoperitoneum was found at laparoscopy and possible splenic rupture was diagnosed. He was managed conservatively and recovered.
On examination at 19 years of age his height was 171X6 cm (lOth-25th centile) and weight 56-25 kg (3rd-lOth centile). He had a thin, aesthenic build and the same facial features as his brother, but with prominent venous patterning over the forehead. The skin was thin and translucent and numerous hypertrophic scars were present. He had marked joint hypermobility of the small joints of his hands, a contracture of the proximal interphalangeal joint of the left little finger, and bilateral pes planus. Cardiovascular examination was normal. The patient's mother had been a slightly built woman whose photographs showed a facies unlike that of her brother or parents. She had prominent eyes, a violaceous colouring to the eyelids, a "pinched" nose, and thin lips. She bruised easily, had a tendency to keloid scar formation, and had hypermobility of the small joints of her hands. At 28 years of age she suffered a spontaneous perforation of Collagen production and secretion were determined by biosynthetically radiolabelling cultured fibroblasts and quantitative sodium dodecylsulphate/polyacrylamide gel electrophoresis. n, the number of different control fibroblast cell lines analysed. Type V collagen is included in total.
the bowel, and died soon afterwards from spontaneous rupture of an isolated right vertebral artery aneurysm. These findings were confirmed at postmortem examination but no diagnosis was assigned. The heart, aorta, and coronary, cerebral (excluding the right vertebral), renal, and pulmonary arteries were normal at postmortem examination.
Results
Biochemical studies on the patient's cultured dermal fibroblasts provided evidence of a type III collagen defect. Fibroblast collagen production was assessed by biosynthetic labelling and quantitative electrophoresis (table 2) . Type III collagen production in our patient was reduced to 32 per cent of control type III collagen production. This dramatic reduction in type III collagen was reflected in the reduced proportion of type III to type I collagen production (4A4 per cent) relative to control fibroblast values (11 6 per cent). Type III collagen secretion was also greatly impaired (36 3 per cent) compared with that of control cells from which 95-8 per cent of type III collagen was secreted during the labelling period. Type I collagen secretion by the type IV Ehlers-Danlos syndrome cells was normal. As collagen secretion is critically dependent on the efficient folding of the three component proal (III) chains into a triple helix, these data suggest that helix formation is disturbed with a consequent increased intracellular degradation of mutant type III collagen resulting in reduced type III collagen production during the labelling period. While increased degradation was not directly demonstrated in this case, it has been a commonly observed phenomenon with type I collagen mutations in osteogenesis imperfecta in which collagen monomer assembly and helix formation are perturbed.5 10 Type III collagen al (III) chains from our patient also exhibited slow electrophoretic migration (fig 2) . Slow electrophoretic migration of collagens is caused by increased levels of post-translational modified lysine residues5 due to underlying structural mutations disturbing efficient assembly of the triple helix and exposing the unfolded a chains to increased enzymatic modification. 6 These data indicate the presence of structural mutation in the gene for the proal(III) chain of type III collagen (COL3A1) in this case of type IV Ehlers-Danlos syndrome.
Characterisation of the precise mutation is in progress. al (1) a2 (1) The importance of proper diagnosis of type IV Ehlers-Danlos syndrome is paramount because the morbidity and mortality associated with diagnostic and therapeutic procedures are increased in this disease. Physicians considering the possibility of type IV EhlersDanlos syndrome should look for relevant clinical signs such as prominent appearing eyes, a thin, delicate, and pinched nose, hollow cheeks, thin lips, and tight, firm, lobeless ears. Joint hypermobility is usually limited to the small joints of the hands and feet, and skin hyperextensibility may be minimal or absent in adults. The skin is characteristically thin and translucent with prominent generalised venous patterning and early ageing.
Discussion
These features may be very subtle in some patients.
Drugs that should be avoided or used with extreme caution in patients with type IV Ehlers-Danlos syndrome include salicylates and non-steroidal anti-inflammatory agents, either alone or in combination with penicillins and cephalosporins. Anticoagulation treatment should be avoided as it may lead to fatal bleeding.' Routine diagnostic arteriography has been associated with aortic rupture,6 22 arterial dissection,22 and massive haemorrhage from arterial puncture sites, '5 even when the diagnosis has been established before investigation. Profuse bleeding and expanding haematomas are commonly reported results of arterial puncture despite normal levels of platelet and coagulation factors. The extreme vascular fragility of this disease cannot be overemphasised. Complications occur in about 65 per cent of patients subjected to angiography.'621 24 In retrospect, aspirin should not have been used in the management of our patient and angiography placed him at considerable risk. Conservative treatment, whenever possible, is recommended.
Our patient represents the first case of type IV Ehlers-Danlos syndrome with symptomatic coronary artery dissection and myocardial infarction. Physicians should consider type IV Ehlers-Danlos syndrome in the differential diagnosis of myocardial infarction secondary to (coronary) arterial dissection, as diagnosis of this heritable disorder has specific implications for management, prognosis, and recurrence risk counselling. The diagnosis can be confirmed by biochemical analysis of type III collagen from the patient's cultured dermal fibroblasts.
